Tenaya Therapeutics, Inc.
NASDAQ:TNYABiotechnology
-$0.00 today
- Market cap
- $69.95M
- Beta
- 2.82
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$0.54
Volume 2.77M
Average 3.79M
TNYA Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Tenaya Therapeutics, Inc.NASDAQ: TNYA
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue remains negative
Q1 FY2026 cost of revenue was $1.76M, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was -$101K. Over 3 fiscal years it compounded at -1.1% a year.
Context
- Cost of revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near $1.76M or moves back toward the trailing-twelve-month quarterly average of -$25.25K.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 8.44M USD
- Year-over-year change
- -0.4%
- 4-year CAGR
- +20.3%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.44M | -0.4% |
| FY2024 | 2024-12-31 | 8.47M | -2.5% |
| FY2023 | 2023-12-31 | 8.69M | -0.3% |
| FY2022 | 2022-12-31 | 8.71M | +116.5% |
| FY2021 | 2021-12-31 | 4.03M | — |
Cost of Revenue vs competitors
How TNYA compares with its peers on the latest reported figures
- TNYA's LTM Mar 2026 cost of revenue of -$101K is the lowest of the 11 companies compared; the peer median is $4.13M.
- Its year-over-year change of -104.8% is the lowest of 7, against a peer median of +20.9%.
- Cost of revenue amounts to 44.9% of revenue for TNYA, versus a peer median of 32.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $68.13M | -46.2% | — | 186.7% | |
| LTM Mar 2026 | $21.94M | — | — | 77.7% | |
| LTM Mar 2026 | $17.11M | +85.4% | +27.3% | 848.5% | |
| LTM Mar 2026 | $6.99M | +800.8% | +50.4% | 48.1% | |
| LTM Mar 2026 | $6.32M | -43.5% | +23.7% | — | |
| LTM Mar 2026 | $1.95M | -96.9% | +0.0% | 17.4% | |
| LTM Mar 2026 | $1.21M | — | — | 1.7% | |
| LTM Mar 2026 | $793.21K | +354.2% | +64.1% | — | |
| LTM Mar 2026 | $391K | — | — | 2.3% | |
| LTM Mar 2026 | $27K | — | — | 0.2% | |
| LTM Mar 2026 | -$101K | -104.8% | -1.1% | 44.9% | |
| Peer median (excluding TNYA) | $4.13M | +20.9% | +27.3% | 32.7% | |
Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| Gross Profit | (4.03M) | (8.71M) | (8.69M) | (8.47M) | (8.44M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 54.39M | 94.54M | 98.04M | 86.74M | 68.61M |
| Selling, General & Admin | 14.39M | 22.37M | 24.47M | 20.74M | 24.72M |
| Operating Expenses | 68.78M | 116.91M | 122.51M | 107.48M | 84.9M |
| Depreciation & Amortization | 4.03M | 8.71M | 8.69M | 8.47M | 8.44M |
| EBITDA | (68.7M) | (114.95M) | (115.4M) | (102.66M) | (82.16M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (72.81M) | (125.62M) | (131.19M) | (115.95M) | (93.33M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 108K | 1.95M | 7.06M | 4.74M | 2.68M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 85K | 1.96M | 7.11M | 4.82M | 2.73M |
| Income Before Tax | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (72.72M) | (123.67M) | (124.08M) | (111.13M) | (90.6M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| EPS (Diluted) | (1.69) | (2.76) | (1.68) | (1.31) | (0.59) |
| Weighted Avg Shares | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
| Weighted Avg Shares (Diluted) | 41.29M | 44.82M | 73.79M | 84.82M | 152.97M |
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
Intrinsic Alpha fair value
Locked
Current Price
$0.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.